Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

被引:2
作者
Leung, Bonnie [1 ]
Shokoohi, Aria [2 ]
Al-Hashami, Zamzam [3 ]
Moore, Sara [4 ]
Pender, Alexandra [5 ]
Wong, Selina K. [6 ,7 ]
Wang, Ying [1 ,6 ]
Wu, Jonn [6 ,8 ]
Ho, Cheryl [1 ,6 ]
机构
[1] BC Canc Vancouver Ctr, Dept Med Oncol, 600 10th Ave West, Vancouver, BC V5Z 4E6, Canada
[2] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada
[3] Sultan Qaboos Comprehens Canc Care & Res Ctr, Dept Med, Muscat, Oman
[4] Ottawa Hosp, Res Inst, Canc Ctr, Ottawa, ON, Canada
[5] Royal Free London NHS Fdn Trust, London, England
[6] Univ British Columbia, Fac Med, Vancouver, BC, Canada
[7] BC Canc, Dept Med Oncol, Victoria, BC, Canada
[8] BC Canc, Dept Radiat Oncol, Vancouver, BC, Canada
关键词
Lung cancer; Older adults; Systemic therapy; Overall survival; Geriatrics; Cancer Treatment; Aging; GERIATRIC ASSESSMENT; 7TH EDITION; CHEMOTHERAPY; CRIZOTINIB; TNM;
D O I
10.1186/s12885-023-10800-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOver the past decade, there has been increasing availability of novel therapeutics with improved tolerability and efficacy for advanced non-small cell lung cancer (NSCLC). The study goals were: to compare the uptake of systemic therapy (ST) before and after the availability of targeted tyrosine kinase inhibitors (TKI) and immunotherapy and to examine the changes in overall survival (OS) over time between younger and older adults with advanced NSCLC.MethodsAll patients with advanced NSCLC referred to British Columbia (BC) Cancer in 2009, 2011, 2015 and 2017 were included. One-year time points were based on molecular testing implementation and funded drug availability: baseline (2009), epidermal growth factor receptor TKI (2011), anaplastic lymphoma kinase TKI (2015) and Programed Death-1 (PD-1) inhibitors (2017). Age groups were <70years and >= 70years. Baseline demographics, simplified comorbidity scores (SCS), disease characteristics, and ST details were collected retrospectively. Variables were compared using X2, Fisher's exact tests and logistic-regression analysis. OS was calculated using the Kaplan-Meier method and compared using the log-rank test.Results3325 patients were identified. Baseline characteristics were compared between ages < 70 years and >= 70 years for each time cohort with significant differences noted in baseline Eastern Cooperative Oncology Group (ECOG) performance status and SCS. The rate of ST delivery trended upwards over time with age <70 years: 2009 44%, 2011 53%, 2015 50% and 2017 52% and age >= 70 years: 22%, 25%, 28% and 29% respectively. Predictors for decreased use of ST for age <70 years: ECOG >= 2, SCS >= 9, year 2011, and smoking history; and age >= 70 years: ECOG >= 2, years 2011 and 2015, and smoking history. The median OS of patients who received ST improved from 2009 to 2017: age >= 70 years 11.4 m vs. 15.0 m.ConclusionsThere was an increased uptake of ST for both age groups with the introduction of novel therapeutics. Although a smaller proportion of older adults received ST, those who received treatment had comparable OS to their young counterpart. The benefit of ST in both age groups was seen across the different types of treatments. With careful assessment and selection of appropriate candidates, older adults with advanced NSCLC appear to benefit from ST.
引用
收藏
页数:11
相关论文
共 30 条
[1]   Older Patients (Still) Left Out of Cancer Clinical Trials [J].
Abbasi, Jennifer .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (18) :1751-1753
[2]  
[Anonymous], 2022, J GERIATR ONCOL
[3]   Targeted Therapies in Older Adults With Solid Tumors [J].
Battisti, Nicolo Matteo Luca ;
Decoster, Lore ;
Williams, Grant R. ;
Kanesvaran, Ravindran ;
Wildiers, Hans ;
Ring, Alistair .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (19) :2128-+
[4]   Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].
Camidge, D. R. ;
Kim, H. R. ;
Ahn, M. -J. ;
Yang, J. C. -H. ;
Han, J. -Y. ;
Lee, J. -S. ;
Hochmair, M. J. ;
Li, J. Y. -C. ;
Chang, G. -C. ;
Lee, K. H. ;
Gridelli, C. ;
Delmonte, A. ;
Garcia Campelo, R. ;
Kim, D. -W. ;
Bearz, A. ;
Griesinger, F. ;
Morabito, A. ;
Felip, E. ;
Califano, R. ;
Ghosh, S. ;
Spira, A. ;
Gettinger, S. N. ;
Tiseo, M. ;
Gupta, N. ;
Haney, J. ;
Kerstein, D. ;
Popat, S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039
[5]  
Canada S, 2022, QUARTERLY
[6]  
Canadian Cancer Society, 2021, EYE CANC
[7]   A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients:: description and comparison with the Charlson's index [J].
Colinet, B ;
Jacot, W ;
Bertrand, D ;
Lacombe, S ;
Bozonnat, MC ;
Daurès, JP ;
Pujol, JL .
BRITISH JOURNAL OF CANCER, 2005, 93 (10) :1098-1105
[8]   Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer [J].
Decoster, L. ;
Kenis, C. ;
Schallier, D. ;
Vansteenkiste, J. ;
Nackaerts, K. ;
Vanacker, L. ;
Vandewalle, N. ;
Flamaing, J. ;
Lobelle, J. P. ;
Milisen, K. ;
De Greve, J. ;
Wildiers, H. .
LUNG, 2017, 195 (05) :619-626
[9]   Treatment of older patients with advanced non-small cell lung cancer: A challenge [J].
Decoster, Lore ;
Schallier, Denis .
JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (04) :528-533
[10]  
Dharmarajan Kavita V, 2021, Am Soc Clin Oncol Educ Book, V41, P1, DOI 10.1200/EDBK_319841